ARCHIVES

FDA Approval of Abraxane Sets Stage for Competition Between Taxane Drugs. Abraxane a Nanotechnology Drug? Sponsor Says Yes, FDA Says.

This article is from The Cancer Letter archive.

Vol. 31 No. 02 | January 14, 2005

Download PDF Visit The Full Archive

Related Articles

Award Fees Show House NCI thinks FCRF Contractors Are Performing

August 15, 1986

In Brief: Administration “Streamlining” Accomplished; DCCR contract Merit Review In Open Session

February 24, 1978

DRCCA Board Gets Tough on Concept Proposals, Okays Several Anyway

November 4, 1983

MRI Network Sought By AACI Nearing Implementation

June 28, 1985

As Shutdown Nears, House Republicans Press For Deeper Cuts and Repeal of Obamacare

September 13, 2013

NCI Board of Scientific Advisors also approved a new SBIR grant program for research on circulating cells in cancer detection.

March 26, 2004